NCT 06007482
Brief Summary
The goal of this clinical trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of ES009 administered intravenously to subjects with advancedat a late stage, far along solid tumors.
Intervention / Treatment
- Drug: ES009
Inclusion Criteria:
- Capable of giving signed informed consenta process in which a patient receives detailed information about a procedure or treatment, including its potential risks, benefits, and alternatives. The patient then has the opportunity to understand the information and voluntarily agree to the procedure or treatment..
- Histological or cytological documentation of unresectable locally advanced or metastatic solid tumors, if 1) disease has progressed despite standard therapy, and no further standard therapy exists; or 2) standard therapy has proven to be ineffective or intolerable or is considered inappropriate.
- At least one measurable lesion per RECIST v1.1.
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status (PS) of 0-1.
- Life expectancy of at least 12 weeks.
- Adequate hematologic, hepatic, renal and coagulation function per protocol.
- Male and female subjects of childbearing potential must be willing to completely abstain or agree to use a highly effective method of contraception per protocol.